Research trials have found that the immunotherapy pembrolizumab more than doubled the ‘progression free survival’ time of patients with a specific subtype of bowel cancer. Honorary Associate Professor Dr Kai-Keen Shiu (UCL Cancer Institute) is Chief Investigator for the trials.
Read: Mail Online, More: UCL News